Search

Displaying results 2951 - 2960 of 8469 in total
  1. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    growth factor (VEGF), basic fibroblast growth factor (bFGF), as well as other pro-angiogenic growth factors. … The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial

  2. Drug

    Alfacalcidol

    go.drugbank.com/drugs/DB01436
    ApprovedInvestigationalNutraceutical

    In Canada, it is marketed as ONE-ALPHA, which manages hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in adults with chronic renal failure. … [L33284] In approving European countries, alfacalcidol is also indicated for managing nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic

  3. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … This discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired

  4. Drug

    ACA 125

    go.drugbank.com/drugs/DB05489
    Investigational

    To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported. … An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies.

  5. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

  6. Drug

    AP1081

    go.drugbank.com/drugs/DB05233
    Experimental

    A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.

  7. Drug

    Icodextrin

    go.drugbank.com/drugs/DB00702
    ApprovedInvestigational

    It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways.

  8. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    Viltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO™.[L15526] … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by the production of shortened and partially functional dystrophin protein.

  9. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. … It is available commercially as the monoclonal antibody portion of the antibody-drug conjugate [brentuximab vedotin].

  10. Drug

    Bleomycin A6

    go.drugbank.com/drugs/DB12992
    Investigational

    Bleomycin A6 (also known as boanmycin) has been used in trials studying the treatment of Squamous Cell Lung Cancer. It was developed in China as an antineoplastic antibiotic. … The development of this drug, apparently, was discontinued.